entertainment -WSS

entertainment

author：entertainment 2025-09-03 09:37:45 - browse：421

Adam's take main illustration — Molly Ferguson/STAT

Anavex Life Sciences is in a tough spot. The serial dissembler of clinical trial results might be forced, finally, to tell the truth when it reads out its next study in Rett syndrome.

What sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials. Twice last year, first in February and then in December, Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs.

If blarcamesine fails to achieve the pre-determined goals of clinical trials, the thinking apparently goes, then just make a post-hoc change to the study goals.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Alabama hospital puts IVF treatments on hold

focus

WSS

He's a Nobel laureate. Critics say he was misleading on Covid

Obesity drugs seen as possible treatment for liver disease MASH

How to convince healthy people to buy insurance

Community Health Systems hospitals under DOJ investigation

Brain injuries and the importance of a second opinion

How to convince healthy people to buy insurance

hotspot

entertainment

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Apple is now the first public company to be valued at $3 trillion

Coloradans with cystic fibrosis could lose access to Trikafta

DIEP, the 'gold standard' of breast reconstruction, is under threat

Brain injuries and the importance of a second opinion

Hepatitis C has a cure — but many Americans still lack access to it

Explaining an after

Apple is now the first public company to be valued at $3 trillion

In utero gene editing: an explainer

leisure time

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

The Harvard botanist who searched for psychedelics in the Amazon

Community Health Systems hospitals under DOJ investigation

A new nitrogen execution bill also undermines medical licensing

focus

explore

focus

hotspot